Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 4, 2007, Pages

  El Khuffash, Afif ^a   Molloy, Eleanor J ^a  

^a NATIONAL MATERNITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

AMINO TERMINAL SEQUENCE; ECHOCARDIOGRAPHY; HEART DISEASE; HEART PERFORMANCE; HUMAN; HUMAN CELL; NEWBORN; NEWBORN DISEASE; NEWBORN MONITORING; PATENT DUCTUS ARTERIOSUS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DUCTUS ARTERIOSUS, PATENT; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REFERENCE VALUES;

EID: 34347334594     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2006.106039     Document Type: Review

References (56)

1. Vesely DL, Cliffs E. Atrial natriuretic hormones. New Jersey: Prentice Hall, 1992.
2. Sudoh T, Kangawa K, Minamino W, et al. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
3. Saito Y, Nakao K, Itoh H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989;158:360-8.
4. Vesely DL, Douglass MA, Dietz JR, et al. Three peptides form the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-40.
5. Singh G, Kuc RE, Maguire JJ, et al. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006;99:183-90.
6. Hunt PH, Yandle TG, Nicholls MG, et al. The amino-terminal portion of probrain natriuretic peptide (proBNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-83.
7. Witthaut R. Science review: natriuretic peptides in critical illness. Crit Care 2004;8:342-9.
8. Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-304.
9. O'Mara PW, Poole SD, Brown N, et al. Regulation of the fetal and newborn ductus arteriosus (da) by natriuretic peptides. E-PAS 2006;59:2875.314.
10. Maack T. Receptors of atrial natriuretic factor. Annu Rev Physiol 1992;54:11-27.
11. Mueller T, Gegenhuber A, Poelz W, et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-12.
12. Soldin SJ, Soldin OP, Boyajian AJ, et al. Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals. Clin Chim Acta 2006;366:304-8.
13. Hammerer-Lercher A, Neubauer E, Muller S, et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7.
14. Tomaro Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002;34:649-59.
15. Abassi Z, Karram T, Ellaham S, et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004;102:223-41.
16. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004;109:3171-81.
17. Troughton RE, Farmpton CM, Yandle, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
18. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
19. Westerlind A, Wahlander H, Lindstedt G, et al. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004;93:340-5.
20. Nir A, Bar-Oz B, Pedes Z, et al. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004;93:603-7.
21. Koch AM, Rauh M, Zink S, et al. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr 2006;95:805-9.
22. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006;27:861- 6.
23. Fried I, Bar-Oz B, Pedes Z, et al. N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. J Pediatr 2006;149:28-31.
24. Nasser N, Perlez Z, Rein AJ, et al. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2006;27:87-90.
25. Cohen S, Springer C, Avital A, et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics 2005;115:1347-50.
26. Gessler P, Knirsch W, Schmitt B, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr 2006;148:372-6.
27. Koch A, Kitzsteiner T, Zink S, et al. Impact of cardiac surgery on plasma levels of B-lype natriuretic peptide in children with congenital heart disease. Int J Cardiol 2007;114:339-44.
28. Shalev A, Nir A, Granot E. Cardiac function in children post-orthotopic liver transplantation: echocardiography parameters and biochemical markers of subclinical cardiovascular damage. Pediatr Transplant 2005;9:718-22.
29. Cowley CG, Bradley JD, Shaddy RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004;25:336- 40.
30. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005;26:1023-30.
31. Hopkins WE, Chen Z, Fukagawa NK, et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2005;109:2872-7.
32. Mir TS, Marohn S, Laer S, et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:e76.
33. Mir TS, Laux R, Hellwege HH, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003;112:896-9.
34. Friedman WF. The intrinsic physiologic properties of the developing heart. Prog Cardiovasc Dis 1972;15:87-111.
35. Subhedar NV. Treatment of hypotension in newborns. Semin Neonatol 2003;51:913-5.
36. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875-8.
37. Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003;57:191-7.
38. Bar-Oz B, Lev-Sagie A, Arad I, et al. N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. Clin Chem 2005;51:926-7.
39. Schwachtgen L, Herrmann M, Georg T, et al. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005;94:399-404.
40. Hammerer-Lercher A, Mair J, Tews G, et al. N-terminal pro-B-type natriuretic peptide concentrations are markedly higher in the umbilical cord blood of newborns than in their mothers. Clin Chem 2005;51:913-5.
41. Bakker J, Gies I, Slavenburg B, et al. Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood. Clin Chem 2004;50:2465.
42. Rauh M, Kocn A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003;49:1563-4.
43. Flynn PA, da Graca RL, Auld PA, et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of parent ductus arteriosus in premature neonates. J Pediatr 2005;147:38-42.
44. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:255-61.
45. Holmstrom H, Omland T. Natriuretic peptides as markers of patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103:79-80.
46. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90:184-91.
47. Sanjeev S, Petersen M, Lua J, et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005;25:709-13.
48. Mathew B, Russell JA, Steinhorn RH, et al. B-type natriuretic peptide (BNP) system in an ovine model of persistent pulmonary hypertension of the newborn (PPHN) [abstract]. Pediatr Res 2006;59:3875.
49. Reynolds EW, Vranicar M, Bada HS. Recombinant human B-Type natriuretic peptide for persistent pulmonary hypertension: a phase 1 study [abstract]. Pediatr Res 2006;59:556.
50. Koulouri S, Acherman RJ, Wong PC, et al. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004;25:341-6.
51. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of inteneukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003;29:1696-702.
52. Rudiger A, Gasser S, Fischler M, et al. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006;34:2140-4.
53. Ueda S, Nishio K, Akai Y, et al. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006;26:134-9.
54. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112:527-34.
55. Roch A, Allardet-Servent J, Michelet P, et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005;33:1001-10.
56. Fried I, Bar-Oz B, Algur N, et al. Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics 2006;118:e1165-8.